Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
INTERVENTIONAL
Inicio: 24 de abr de 2025
ID: NCT06875310
Reclutando
ClinicalTrials.gov
Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)
OBSERVATIONAL
Inicio: 4 de abr de 2024
ID: NCT07168876
Completado
Fase 3
ClinicalTrials.gov
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
INTERVENTIONAL
Inicio: 23 de dic de 2009
ID: NCT01000025
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
INTERVENTIONAL
Inicio: 3 de sept de 2013
ID: NCT01855750
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
INTERVENTIONAL
Inicio: 21 de abr de 2021
ID: NCT04700124
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
INTERVENTIONAL
Inicio: 23 de jun de 2017
ID: NCT03151408
Completado
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
INTERVENTIONAL
Inicio: 25 de jun de 2011
ID: NCT01351415
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
INTERVENTIONAL
Inicio: 10 de mar de 2011
ID: NCT01327885
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
INTERVENTIONAL
Inicio: 25 de jun de 2024
ID: NCT06496178
Completado
Fase 1
ClinicalTrials.gov
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
INTERVENTIONAL
Inicio: 1 de abr de 2005
ID: NCT00346255
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
INTERVENTIONAL
Inicio: 8 de feb de 2019
ID: NCT03673501
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
INTERVENTIONAL
Inicio: 1 de jul de 2021
ID: NCT04906395
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
INTERVENTIONAL
Inicio: 13 de may de 2025
ID: NCT06925737
Reclutando
Fase 1
ClinicalTrials.gov
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
INTERVENTIONAL
Inicio: 17 de sept de 2024
ID: NCT06333951
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma
INTERVENTIONAL
Inicio: 1 de mar de 2006
ID: NCT00257205
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
INTERVENTIONAL
Inicio: 9 de sept de 2015
ID: NCT02369874
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy
INTERVENTIONAL
Inicio: 1 de may de 2003
ID: NCT00171340
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
INTERVENTIONAL
Inicio: 1 de dic de 2010
ID: NCT01170663
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 14 de feb de 2023
ID: NCT05722015
Completado
Fase 3
ClinicalTrials.gov
Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00678535
Anterior
1
...
60
61
62
...
434
Siguiente
Filtros